These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 34660022)

  • 1. Male Breast Cancer: Clinical, Demographical, and Pathological Features in a Cohort of 41 Patients.
    Koseci T; Haksöyler V; Olgun P; Koyuncu MB; Bozkurt Duman B; Çil T
    Cureus; 2021 Sep; 13(9):e17812. PubMed ID: 34660022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
    Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
    Wong Y; Raghavendra AS; Hatzis C; Irizarry JP; Vega T; Horowitz N; Barcenas CH; Chavez-MacGregor M; Valero V; Tripathy D; Pusztai L; Murthy RK
    Oncologist; 2019 Mar; 24(3):313-318. PubMed ID: 30139836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Jin L; Chen K; Tan C; Li J; Luo J; Yang Y; Li Y; Li S; Zhu L; Hu Y; Liu F; You Q; Peng M; Jiang Z; Liu Q
    Oncologist; 2020 Aug; 25(8):e1170-e1180. PubMed ID: 32476192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of non-metastatic male breast cancer: 118 patients.
    Arslan UY; Oksüzoğlu B; Ozdemir N; Aksoy S; Alkış N; Gök A; Kaplan MA; Gümüş M; Berk V; Uncu D; Baykara M; Colak D; Uyetürk U; Türker I; Işıkdoğan A
    Med Oncol; 2012 Jun; 29(2):554-60. PubMed ID: 21573973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological and Immunohistochemical Characteristics in Male Breast Cancer: A Retrospective Case Series.
    Masci G; Caruso M; Caruso F; Salvini P; Carnaghi C; Giordano L; Miserocchi V; Losurdo A; Zuradelli M; Torrisi R; Di Tommaso L; Tinterri C; Testori A; Garcia-Etienne CA; Gatzemeier W; Santoro A
    Oncologist; 2015 Jun; 20(6):586-92. PubMed ID: 25948676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients.
    Li X; Yang J; Krishnamurti U; Huo L; Ward KC; O'Regan R; Peng L
    Clin Breast Cancer; 2017 Aug; 17(5):356-366. PubMed ID: 28576631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
    Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
    Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-Negative Metaplastic Breast Carcinoma: Association of Epidermal Growth Factor Receptor Expression With Prognostic Parameters and Clinical Outcome.
    Munawar S; Haider R; Ali SM; Yaqeen SR; Islam S; Asghar IA; Afzal A; Zia S; Irfan M; Hashmi AA
    Cureus; 2021 May; 13(5):e15006. PubMed ID: 34150374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall Survival of Men and Women With Breast Cancer According to Tumor Subtype: A Population-based Study.
    Leone J; Zwenger AO; Leone BA; Vallejo CT; Leone JP
    Am J Clin Oncol; 2019 Feb; 42(2):215-220. PubMed ID: 30499840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
    Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
    Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
    Park HS; Sohn J; Kim SI; Park S; Park HS; Gho SG; Chung HC; Paik S; Kim GM
    Breast Cancer Res Treat; 2017 Jun; 163(2):255-262. PubMed ID: 28243895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of androgen receptor (AR) in HER2-enriched metastatic breast cancer.
    Wang X; Bi X; Huang Z; Huang J; Xia W; Shi W; Yuan Z
    Endocr Relat Cancer; 2020 Apr; 27(4):199-208. PubMed ID: 31958314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metaplastic Breast Carcinoma: Clinicopathological Parameters and Prognostic Profile.
    Haroon S; Zia S; Shirazi UA; Ahmed O; Asghar IA; Diwan MA; Afzal A; Irfan M; Ali SJ; Hashmi AA
    Cureus; 2021 Apr; 13(4):e14347. PubMed ID: 33987039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast Cancer in Men: a Report from the Department of Radiation Oncology in Kermanshah Province, Iran.
    Amirifard N; Sadeghi E
    Asian Pac J Cancer Prev; 2016; 17(5):2593-6. PubMed ID: 27268636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
    Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
    Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
    Cabel L; Carton M; Cheaib B; Pierga JY; Dalenc F; Mailliez A; Levy C; Jacot W; Debled M; Leheurteur M; Desmoulins I; Lefeuvre C; Gonçalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Perrocheau G; Piot I; Pérol D; Simon G; Lerebours F
    Breast Cancer Res Treat; 2019 Jan; 173(2):397-406. PubMed ID: 30357526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Male Breast Cancer and Hyperestrogenemia: A Thirteen-Year Review.
    Tariq KB; Al-Saffar F; Ibrahim S; Pham D; Farhangi A; Rana F; Zaiden R
    World J Oncol; 2014 Apr; 5(2):55-61. PubMed ID: 29147378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
    Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
    BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
    Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
    Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.